Cargando…
Anti-TIGIT therapies for solid tumors: a systematic review
Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T...
Autores principales: | Rousseau, A., Parisi, C., Barlesi, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030909/ https://www.ncbi.nlm.nih.gov/pubmed/36933320 http://dx.doi.org/10.1016/j.esmoop.2023.101184 |
Ejemplares similares
-
A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021) -
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
por: Yeo, Jinah, et al.
Publicado: (2021) -
Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis
por: Xiao, Kunmin, et al.
Publicado: (2021) -
TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020) -
Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)